Bli medlem
Bli medlem

Du är här

2015-04-08

PCI Biotech Holding: PCI Biotech to present at the World Vaccine Congress 2015

Lysaker, April 8, 2015 - PCI Biotech will be presenting at the World Vaccine
Congress 2015 at Walter E. Washington Convention Center, Washington D.C. In
its 15th year, World Vaccine Congress remains the industry's definitive
vaccine industry conference and exhibition for major vaccine players and
their respective senior level representatives.

The presentation"Photochemical internalisation (PCI) - an innovative
technology for
CTL-induction"
will be held April 8 local time 10:10 and the company will be represented by
Dr. Anders Høgset, CSO. The presentation will be available at PCI Biotech's
webpage under "News".

About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company headquartered in
Norway and listed on the Oslo Stock Exchange (Axess). The company is
developing therapeutic products based on its proprietary photochemical
internalization (PCI) technology. Originating from world leading research at
the Norwegian Radium Hospital, the PCI technology works by inducing triggered
endosomal release and may be used to unlock the true therapeutic potential of
a wide array of modalities, such as small molecules, ADCs and siRNA. Two
programs are currently in clinical development in patient populations with a
high unmet medical need; recurrent head and neck cancer (phase II) and bile
duct cancer (phase I/II).

The company is also developing PCI as a CTL induction technology for
therapeutic and prophylactic vaccination. It has been demonstrated both in
vivo and ex vivo that PCI significantly increases the number of activated
antigen-specific CTLs (Cytotoxic T Lymphocytes) by enhancing the MHC I
antigen presentation of antigen presenting cells. When applied more
specifically to the emerging field of cancer immunotherapy, PCI can be used
to enhance the important cytotoxic effect of therapeutic cancer vaccines. PCI
Biotech follows a strategy to create value by improving the effect both of
existing cancer drugs and by realizing the large potential in new
therapeutics, including therapeutic vaccines.

For more information visit:www.pcibiotech.com

For further information, please contact
Ronny Skuggedal, CFO
rs@pcibiotech.no

Mobile: +47 9400 5757

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCI Biotech Holding via Globenewswire

HUG#1909454

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.